The 2020 edition of the health care catalog adjustment curtain is about to open, will help to accelerate the release of innovative drugs.

On August 3rd, the State Health Insurance Administration released the Work Programme for the Adjustment of the National Health Insurance Drug Catalog 2020 (draft for comments) (hereinafter referred to as the Draft for Comments), which means that a new round of adjustment of China's medical insurance catalogue is about to begin.
Draft for Comments proposed that seven types of drugs could be included in the 2020 drug catalogue to be added to the scope of drugs, and three categories of drugs are transferred out of the target.
industry believes that from the direction of adjustment, more innovative drugs, including domestic new drugs, will be included in health insurance in the future, which will also help to accelerate the release of innovative drugs.
2020 version of the medical insurance catalog adjustment to open 7 categories of drugs can be included in the proposed new scope of a batch of drugs will be transferred out of the drug catalog.
This Draft for Comments clearly states that drugs that have been revoked, revoked or cancelled by the State Drug Administration to prove drug approval documents, and that drugs assessed to be more risky than beneficial will be transferred out of the catalogue, taking into account such factors as clinical value, adverse reactions, and drug economy.
the standard of payment is significantly higher than that of other drugs in the field of treatment, and drugs that have taken up more funds in recent years are also targeted for transfer.
It is worth mentioning that, in addition to the above-mentioned drugs, on 31 July, the Interim Measures for the Administration of Essential Medical Insurance Drugs issued by the State Health Insurance Administration made it clear that eight categories of drugs, such as drugs and health-care drugs, which mainly play a tonic role, are no longer included in the medical insurance catalogue.
interim measures will come into effect on September 1, 2020.
a batch of varieties will have the opportunity to be transferred to the 2020 version of the health insurance catalog.
The Draft for Comments" proposes that drugs for the treatment of respiratory diseases related to neo-corona pneumonia should be included in the National Essential Medicines Directory (2018 edition); List of children's medicines, and drugs approved for listing by the State Drug Administration by December 31, 2019;
this adjustment declaration will be completed in December 2020, the enterprise declaration time is expected to be August-September, negotiations and bidding is expected to be set in October-November, the need for the attention of pharmaceutical companies.
Health insurance adjustment is becoming more and more scientific, perfect will help innovative drug release speed up from the 2020 version of the medical insurance catalog into the transfer out of the general direction, high adverse reaction rate, high prices, clinically not recognized but a large number of drugs will be likely to lose the eligibility to health insurance.
more innovative drugs, including domestic new drugs and imported new drugs, will be included in health insurance.
For example, article 3 refers to the inclusion of new drugs in clinically urgent need abroad, the encouragement of generic drug catalogues or the encouragement of research and development to declare lists of children's medicines, which have been approved for market by the State Drug Administration by 31 December 2019; During December 31, 2019, the State Drug Administration approved the listing of drugs (including new active ingredients, new dosage forms) in accordance with the application procedure for the registration of new drugs, and this time explicitly included "the second batch of national organizations of drugs centralized procurement of selected drugs" into the medical insurance catalogue, mostly for new drugs.
, in fact, from the list of health insurance drugs in recent years, there is no shortage of innovative drugs.
, for example, in the 2019 health-care negotiations, several innovative drugs were included in the national health-care list through significant price cuts, including Gilead Sciences' hepatitis B and hepatitis C treatments.
The industry believes that, with the normalization of volume procurement and medical insurance adjustment work is becoming more scientific, perfect, innovative drugs overall benefit, innovative drug price reduction into health insurance after the large probability can achieve "price-for-volume", will help to accelerate the amount of innovative drugs.
, because most innovative drugs have high barriers and fewer manufacturers, the structural dividends of health insurance tend to be concentrated in a small number of companies with outstanding research and development capabilities.
and for generics with low clinical value and unclear drug technology, it may be difficult for companies to survive in the future pharmaceutical environment if they do not transform and innovate in a timely manner.
.